GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Clearmind Medicine Inc.
Clearmind Medicine is a biotech company developing psychedelic drugs for addiction treatment. Its stock price is a venture capital bet on the legalization and medical use of these substances.
Share prices of companies in the market segment - Pharma psycho
Clearmind Medicine is a Canadian biotech company developing psychedelic-based drugs for the treatment of addictions such as alcoholism. We've categorized it as "Pharma: Psycho." The chart below shows how investors view this emerging and promising pharmaceutical segment.
Broad Market Index - GURU.Markets
Clearmind Medicine is a Canadian biotech company developing psychedelic-based medications for the treatment of alcohol addiction. It is a component of the GURU.Markets index. The chart below shows the US market. See how this company's stock compares to the US market.
Change in the price of a company, segment, and market as a whole per day
CMND - Daily change in the company's share price Clearmind Medicine Inc.
For Clearmind Medicine Inc., which works with psychedelics, daily volatility reflects sensitivity to clinical trial data. This metric is an important element in assessing risks in this innovative field.
Daily change in the price of a set of shares in a market segment - Pharma psycho
Clearmind Medicine is researching psychedelic compounds for the treatment of mental disorders such as alcohol addiction. This is a highly speculative and volatile sector of biotech. The chart below reflects average fluctuations in this niche, serving as an indicator of risks and investor expectations.
Daily change in the price of a broad market stock, index - GURU.Markets
Clearmind Medicine is a biotech company developing psychedelic-based drugs. News of clinical trials in this cutting-edge field triggers sharp stock price movements, which in turn contribute to the overall "noise" and market dynamics.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Clearmind Medicine Inc.
For Clearmind Medicine Inc., the year-to-date performance is a story about psychedelic drug development. Its 12-month market cap depends entirely on progress in preclinical and clinical trials of its compounds for treating alcohol addiction. Success could lead to a breakthrough in this innovative, yet high-risk, field of medicine.
Annual dynamics of market capitalization of the market segment - Pharma psycho
Clearmind, as a biotech company developing psychedelic-based drugs, is a high-risk bet on the future of psychiatry. Its momentum is completely disconnected from the sector and dependent on news of clinical trials and legalization, reflecting the speculative nature of this innovative approach.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Clearmind Medicine, a Canadian biopharmaceutical company researching psychedelics for addiction treatment, is another player in this revolutionary field. Its year-over-year market capitalization reflects both the high investor interest in the potential of psychedelic medicine and the significant regulatory risks.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Clearmind Medicine Inc.
Clearmind is a biopharmaceutical company developing psychedelic therapeutics. Its monthly growth is entirely dependent on progress in its clinical programs. News about research results and regulatory changes are the main drivers.
Monthly dynamics of market capitalization of the market segment - Pharma psycho
Clearmind Medicine is a Canadian biotech company developing psychedelic-based drugs for the treatment of addiction and mental health disorders. This is a high-risk field. The psychopharmaceutical sector chart reflects both the enormous potential and the regulatory hurdles facing companies like Clearmind.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Clearmind Medicine is a Canadian biotech company researching psychedelics for addiction treatment. Its stock is highly speculative, depending entirely on legislative changes and clinical trial results. It has no connection to the broader market; it's a bet on legalization and a medical breakthrough.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Clearmind Medicine Inc.
Clearmind Medicine, a company researching psychedelics for addiction treatment, operates at the intersection of medicine and changing social norms. Its weekly stock price performance reflects advances in preclinical research and news of the legalization of psychedelic therapy.
Weekly dynamics of market capitalization of the market segment - Pharma psycho
Clearmind Medicine develops psychedelic drugs for the treatment of addictions and mental disorders. This is one of the most speculative areas in biotech. The chart clearly demonstrates how its shares react to the slightest news, living in isolation from the rest of the pharmaceutical market.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Clearmind Medicine develops psychedelic drugs. Its shares are driven by news of legalization and trial results. The chart will show how disconnected its performance is from the broader market and how it operates according to the industry's own, highly volatile laws.
Market capitalization of the company, segment and market as a whole
CMND - Market capitalization of the company Clearmind Medicine Inc.
Clearmind Medicine's market capitalization reflects investors' bets on its developments in psychedelic medicine. The chart shows the market's belief that its MEAI molecule will be able to treat alcohol addiction. Its high volatility and low price reflect both the company's enormous potential to solve a serious problem and the high risk of clinical failure.
CMND - Share of the company's market capitalization Clearmind Medicine Inc. within the market segment - Pharma psycho
Clearmind Medicine is a Canadian company developing psychedelic drugs for the treatment of addictions such as alcoholism. Its market share in the pharmaceutical sector is negligible, but it operates at the forefront of science. Its capitalization is a bet on its research and the potential to transform approaches to treating addictive disorders.
Market capitalization of the market segment - Pharma psycho
Below is a chart showing the total value of the entire pharmaceutical sector focused on treating mental disorders. For Clearmind Medicine, which works with psychedelics, this line is a map of the scientific revolution. Its growth demonstrates how investors are beginning to believe in the therapeutic potential of these once-banned substances.
Market capitalization of all companies included in a broad market index - GURU.Markets
Clearmind Medicine is a Canadian company developing psychedelic drugs for addiction treatment. Its market capitalization is another bet on the renaissance of psychedelics in medicine. Its market share is driven by the scientific search for new treatments.
Book value capitalization of the company, segment and market as a whole
CMND - Book value capitalization of the company Clearmind Medicine Inc.
Clearmind Medicine is a biopharmaceutical company developing psychedelic-based drugs for the treatment of addiction. Its book value is the financial resources it has available for preclinical research. How has this innovative scientific capital changed? The chart below shows.
CMND - Share of the company's book capitalization Clearmind Medicine Inc. within the market segment - Pharma psycho
Clearmind Medicine Inc. is developing psychedelic-based therapies for addiction treatment. Its scientific work requires a dedicated laboratory for the research and development of new MEAI-based compounds. The chart shows the company's share of the physical R&D infrastructure for this cutting-edge field.
Market segment balance sheet capitalization - Pharma psycho
Clearmind Medicine is a biopharmaceutical company. Pharmaceuticals, as the chart shows, are both knowledge- and capital-intensive. Clearmind focuses on drug development, and its capital is its intellectual property and R&D infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
Clearmind Medicine's assets are not clinics, but capital and intellectual property focused on the development of psychedelic drugs for the treatment of addictions, particularly alcoholism. The book value reflects the financial resources for preclinical and clinical research.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Clearmind Medicine Inc.
Clearmind Medicine is a biopharmaceutical company focused on psychedelics for addiction treatment. Its market capitalization is a speculative bet on the legalization and medical use of these substances to address serious health issues.
Market to book capitalization ratio in a market segment - Pharma psycho
Clearmind Medicine is a company developing psychedelic drugs for addiction treatment. This is a highly speculative field. Its market valuation on this chart reflects investors' pure faith that psychedelics will become mainstream in medicine.
Market to book capitalization ratio for the market as a whole
Clearmind Medicine is researching psychedelics for addiction treatment. Like other companies in this sector, its market value is based almost entirely on expectations of future breakthroughs. This chart demonstrates the market's appetite for high-risk investments in revolutionary approaches to treating mental disorders.
Debts of the company, segment and market as a whole
CMND - Company debts Clearmind Medicine Inc.
Clearmind, a company researching psychedelics for addiction treatment, is in the preclinical stage and is entirely dependent on external funding. This timeline reflects the initial, but significant, investment required to validate the scientific hypothesis and prepare for clinical trials.
Market segment debts - Pharma psycho
Clearmind Medicine is a Canadian biopharmaceutical company developing psychedelic-based medications for the treatment of addictions, particularly alcoholism. This chart shows how the startup, in this cutting-edge but risky field of medicine, is raising capital to fund its preclinical and early clinical trials.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Clearmind Medicine Inc.
Clearmind Medicine is a biotech company developing psychedelic-based drugs for the treatment of addiction and mental disorders. Research in this cutting-edge but highly regulated field is extremely expensive. This chart shows how the company uses debt to finance its high-risk but potentially breakthrough research.
Market segment debt to market segment book capitalization - Pharma psycho
Clearmind Medicine is a Canadian biopharmaceutical company developing psychedelic drugs for the treatment of alcohol addiction. This is a risky but potentially disruptive field. This chart shows how the company finances its research, comparing its debt structure to the broader biotech landscape.
Debt to book value of all companies in the market
Clearmind Medicine is a biotech company researching psychedelics for the treatment of addiction and mental disorders. This is a cutting-edge, but high-risk, field. How heavily does the company rely on debt for its research? This chart of total market debt helps assess the riskiness of its financial strategy.
P/E of the company, segment and market as a whole
P/E - Clearmind Medicine Inc.
Clearmind Medicine is a Canadian biopharmaceutical company developing psychedelic-based medications for the treatment of alcohol addiction. This chart shows speculative investor interest in this area. The valuation is highly volatile and depends on research progress and regulatory changes.
P/E of the market segment - Pharma psycho
Clearmind Medicine is a Canadian biotech company developing psychedelic drugs for the treatment of addiction and mental disorders. This chart illustrates the average valuation in the psychopharmaceutical sector, where investors are betting on the potential of psychedelics to create breakthrough treatments.
P/E of the market as a whole
Clearmind Medicine Inc. is a biotech company focused on the discovery and development of psychedelic drugs for the treatment of mental disorders such as alcoholism. This chart reflects overall investor interest in the psychedelics sector. It helps understand whether CMND's valuation reflects speculative interest in this emerging field or general trends in biotech.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Clearmind Medicine Inc.
Clearmind Medicine is a biotech company developing psychedelic-based medications for the treatment of addiction, particularly alcoholism. Its approach targets the root of the problem at the neurobiological level. This chart reflects investors' speculative expectations regarding the future medical applications of psychedelics and the success of the company's research.
%20P%2FE%20Clearmind%20Medicine%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Clearmind-Medicine-Inc.&v=1772676511631 "Chart of the company's future (projected) P/E Clearmind Medicine Inc.")
Future (projected) P/E of the market segment - Pharma psycho
Clearmind Medicine is a psychedelic pharmaceutical company developing drugs based on MEA for the treatment of alcoholism and other addictions. The chart reflects the sector's future profit expectations. It helps understand how much investors believe in the therapeutic potential of this compound and the company's future success.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-psycho&v=1772676511658 "Future (projected) P/E graph of the market segment - Pharma psycho")
Future (projected) P/E of the market as a whole
Clearmind Medicine is a Canadian biotech company developing psychedelic drugs for the treatment of alcohol addiction and other disorders. This sector is in its early stages of development. This overall risk appetite chart is an indicator of investor willingness to fund such disruptive, yet high-risk, medical advances.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772676511677 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Clearmind Medicine Inc.
Clearmind Medicine Inc. is a biopharmaceutical company developing psychedelic drugs for the treatment of alcohol addiction and other mental disorders. Financial indicators reflect preclinical research expenditures. This chart shows investments in a new and promising approach to addiction treatment.
Profit of companies in the market segment - Pharma psycho
Clearmind Medicine Inc. is a biotech company focused on the discovery and development of psychedelic drugs for the treatment of mental disorders such as alcohol addiction. This chart reflects the financial health of the nascent psychedelic medicine sector, where the scientific potential is enormous, but the road to commercialization is long and risky.
Overall market profit
Clearmind Medicine Inc. is a biopharmaceutical company developing psychedelic-based medications for the treatment of addictions and mental disorders. The company is at the forefront of innovation. Its success depends on clinical trial results and regulatory changes, not on the macroeconomic trends visible in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Clearmind Medicine Inc.
Clearmind Medicine is a Canadian biotech company developing psychedelic drugs for the treatment of addictions such as alcoholism. Future profits depend on clinical success and the destigmatization of psychedelic therapy. This chart reflects analysts' speculative expectations regarding the resurgence of this medical field.
%20profit%20of%20the%20company%20Clearmind%20Medicine%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Clearmind-Medicine-Inc.&v=1772676511793 "Graph of future (projected) profit of the company Clearmind Medicine Inc.")
Future (predicted) profit of companies in the market segment - Pharma psycho
Clearmind Medicine is a biopharmaceutical company developing psychedelic-based medications for the treatment of addictions such as alcoholism. The company is investigating the potential of the compound MEAI to reduce alcohol cravings. This chart shows revenue projections for the psychopharmaceutical sector, providing context for evaluating Clearmind's cutting-edge research.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-psycho&v=1772676511828 "Graph of future (predicted) profits of companies in a market segment - Pharma psycho")
Future (predicted) profit of the market as a whole
Clearmind Medicine Inc. is a biopharmaceutical company developing psychedelic drugs for the treatment of addiction. Its success depends on clinical trials and regulatory changes. This revenue expectation schedule impacts the availability of venture capital for funding in such an innovative but risky field.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772676511840 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Clearmind Medicine Inc.
Clearmind Medicine is a psychedelic pharmaceutical company developing drugs for the treatment of alcoholism. There is no revenue in the research phase. This chart reflects investors' speculative belief that the company will offer a revolutionary treatment for addiction.
P/S market segment - Pharma psycho
Clearmind Medicine is a biotech company focused on discovering and developing psychedelic drugs for the treatment of mental disorders, particularly alcohol addiction. The company is at the forefront of the resurgence of interest in psychedelic medicine. This chart shows the average revenue estimate for the sector, providing insight into market expectations for this field.
P/S of the market as a whole
Clearmind Medicine is a biotech company developing psychedelic drugs for the treatment of alcohol addiction and other mental disorders. This chart shows that the valuation of such companies is based on the enormous expectations of a revolution in psychiatry, not on current financial performance.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Clearmind Medicine Inc.
Clearmind Medicine is a biopharmaceutical company developing psychedelic-based therapeutics for the treatment of addiction and mental disorders. Its revenue valuation is crucial, reflecting investor expectations for the success of its research and the changing regulatory environment that could legalize psychedelic therapy.
%20P%2FS%20Clearmind%20Medicine%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Clearmind-Medicine-Inc.&v=1772676511946 "The graph of the company's future (projected) P/S Clearmind Medicine Inc.")
Future (projected) P/S of the market segment - Pharma psycho
Clearmind Medicine is a psychedelic pharmaceutical company developing drugs based on the compound MEAI for the treatment of alcoholism and other addictions. This chart shows how investors view the company's future earnings relative to the pharmaceutical sector. It demonstrates the market's faith in its innovative approach to addiction treatment and the potential of its developments.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-psycho&v=1772676511957 "Future (projected) P/S market segment graph - Pharma psycho")
Future (projected) P/S of the market as a whole
Clearmind Medicine is a biopharmaceutical company developing psychedelic-based medications for the treatment of addiction and mental disorders. The company's future depends on the success of clinical trials and regulatory changes. This market outlook chart reflects growing investor interest in the potential of psychedelic medicine.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772676511980 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Clearmind Medicine Inc.
This chart shows the financial performance of Clearmind Medicine, a Canadian biopharmaceutical company developing psychedelic-based drugs for the treatment of alcoholism. Being in the preclinical stage, the company has no commercial revenue.
Sales of companies in the market segment - Pharma psycho
Clearmind Medicine is a biopharmaceutical company developing psychedelic drugs for the treatment of addiction and mental disorders. Currently in the preclinical stage, it has no revenue yet. Its future revenue will depend on the success of its research in this innovative and rapidly developing field of medicine.
Overall market sales
Clearmind Medicine Inc. is a biopharmaceutical company researching psychedelic compounds for the treatment of mental disorders such as alcoholism. The company operates at the forefront of innovation in psychiatry. This general economics chart does not capture the dynamics of this disruptive sector, where value is created through scientific potential and changing treatment paradigms.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Clearmind Medicine Inc.
Clearmind Medicine is a psychedelic pharmaceutical company developing psychedelic-based medications for the treatment of addiction and mental disorders. Future revenue is dependent on the success of clinical trials. This chart reflects analyst expectations for the potential growth of the psychedelic medicine market and the commercial potential of the company's developments.
%20sales%20of%20the%20company%20Clearmind%20Medicine%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Clearmind-Medicine-Inc.&v=1772676512092 "Schedule of future (projected) sales of the company Clearmind Medicine Inc.")
Future (projected) sales of companies in the market segment - Pharma psycho
Clearmind Medicine Inc. is a company developing psychedelic drugs for the treatment of addictions and mental disorders. This chart shows the forecast for the CNS drug market. Is the psychedelic therapy market expected to grow as stigma is de-stigmatized and approvals are obtained? This reflects the potential of this field.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-psycho&v=1772676512120 "Schedule of future (projected) sales of companies in the market segment - Pharma psycho")
Future (projected) sales of the market as a whole
Clearmind Medicine is a psychedelic pharmaceutical company developing drugs for addiction treatment. Its success depends on the results of clinical trials and changes in legislation regarding psychedelics. The general economic cycles reflected in this chart have no bearing on the scientific and regulatory processes that will determine the company's future.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772676512123 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Clearmind Medicine Inc.
Clearmind Medicine is a biopharmaceutical company developing psychedelic-based treatments for addiction and mental health disorders. This chart reflects its financial performance in early-stage research. Profitability is a long-term goal, dependent on the success of its innovative approaches and changes in the regulation of psychedelic medicine.
Market segment marginality - Pharma psycho
Clearmind Medicine Inc. is a biopharmaceutical company developing psychedelic-based medications for the treatment of addiction and mental disorders. This chart reflects its financial position at the R&D stage, where profitability is a future goal dependent on the success of clinical trials and changes in the legal status of psychedelic therapy.
Market marginality as a whole
Clearmind Medicine is a psychedelic pharmaceutical company developing drugs for addiction treatment. It operates at the forefront of innovation in psychiatry. This total return chart reflects investor appetite for high-risk but potentially revolutionary biotech projects.
Employees in the company, segment and market as a whole
Number of employees in the company Clearmind Medicine Inc.
Clearmind Medicine is a biotech company developing psychedelic-based drugs for the treatment of addiction and mental disorders. Its very small staff consists of key scientists and managers. This graph shows the compact team leading its development through the early, preclinical stages of research.
Share of the company's employees Clearmind Medicine Inc. within the market segment - Pharma psycho
Clearmind Medicine is a psychedelic pharmaceutical company developing drugs for addiction treatment. Its work is in the early stages of research and requires a small but highly specialized team of scientists. This graph shows the company's market share, reflecting its R&D focus on a new and promising area of medicine.
Number of employees in the market segment - Pharma psycho
Clearmind Medicine is a Canadian biotech company researching psychedelic compounds for the treatment of alcohol addiction and other mental health disorders. This chart shows employment in the psychopharmaceutical sector. Clearmind aims to develop next-generation drugs that could offer breakthroughs in addiction treatment.
Number of employees in the market as a whole
Clearmind Medicine is a biopharmaceutical company researching psychedelics for addiction treatment. This is a cutting-edge and controversial field. The company's growth depends on scientific breakthroughs and regulatory changes. It represents the vanguard of medicine, shaping an entirely new labor market that is invisible in the mainstream economy.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Clearmind Medicine Inc. (CMND)
Clearmind Medicine is a biotech company working in the psychedelic field and developing psychedelic-based drugs (for example, for the treatment of alcoholism). This chart shows a high speculative market valuation. It reflects the market value per scientist, which is a bet on a breakthrough in this emerging field of medicine.
%20of%20the%20company%20Clearmind%20Medicine%20Inc.%20(CMND)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Clearmind-Medicine-Inc.-CMND&v=1772676512220 "Chart of market capitalization per employee (in thousands of dollars) of the company Clearmind Medicine Inc. (CMND)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma psycho
Clearmind Medicine (CMND) is a Canadian biopharmaceutical company developing psychedelic drugs for the treatment of alcohol addiction and other disorders. In this cutting-edge field, this chart reflects investors' faith in the therapeutic potential of psychedelics. The high valuation per employee is a bet on the future legalization and medical use of these substances.
%20by%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-psycho&v=1772676512221 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma psycho")
Market capitalization per employee (in thousands of dollars) for the overall market
Clearmind Medicine is a biopharmaceutical company developing psychedelic-based drugs for addiction treatment. Its valuation is based on future potential. The chart shows a high cost per employee, as investors see the breakthrough nature of this research and the potential to create a new class of drugs.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772676512269 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Clearmind Medicine Inc. (CMND)
Clearmind Medicine is a preclinical biotech company developing psychedelic drugs (based on MEAI) for the treatment of addictions (such as alcohol addiction). This graph shows the net loss per employee. It reflects that each scientist at the company represents an R&D investment, funded to test hypotheses.
%20Chart%20Clearmind%20Medicine%20Inc.%20(CMND)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Clearmind-Medicine-Inc.-CMND&v=1772676512390 "Company Profit Per Employee (in thousands of dollars) Chart Clearmind Medicine Inc. (CMND)")
Profit per employee (in thousands of dollars) in the market segment - Pharma psycho
Clearmind Medicine Inc. is a Canadian biotech company developing psychedelic drugs for the treatment of addiction and mental disorders. In this revolutionary field of pharmaceuticals, team effectiveness is determined by the speed of research. The chart reflects the financial return per employee, which is a leading indicator of the potential of their developments.
%20in%20the%20market%20segment%20-%20Pharma%20psycho&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-psycho&v=1772676512463 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma psycho")
Profit per employee (in thousands of dollars) for the market as a whole
Clearmind Medicine is a biotech company working in the psychedelic field. They are developing a treatment for alcoholism based on the psychedelic compound MEAI. This is an R&D business. This chart, showing average profitability, helps to understand the contrast with biotech, where a team of scientists burns through capital in hopes of drug approval.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772676512497 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Clearmind Medicine Inc. (CMND)
Clearmind Medicine is a biopharmaceutical company working in the field of psychedelic medicine. During the research phase, there is no revenue per employee. This graph is important as it indicates enormous potential: the legalization and approval of such drugs could create a new multi-billion dollar market and lead to explosive growth.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Clearmind-Medicine-Inc.-CMND&v=1772676512520 "Sales chart per company employee Clearmind Medicine Inc. (CMND)")
Sales per employee in the market segment - Pharma psycho
Clearmind Medicine (CMND) is a Canadian preclinical biotech developing psychedelic-based drugs (specifically MEAI) for the treatment of addictions (alcoholism) and other disorders. They have no commercial revenue. This chart, showing the average revenue in the sector, serves as a barometer of CMND's R&D staffing efficiency.
Sales per employee for the market as a whole
Clearmind Medicine is a biotech company working at the forefront of science. They are developing psychedelic-based medications for the treatment of addiction. Currently, their business is focused on R&D. This chart reflects their pre-commercial phase: the company is investing in research and has no sales revenue.
Short shares by company, segment and market as a whole
Shares shorted by company Clearmind Medicine Inc. (CMND)
Clearmind (CMND) is another company in the psychedelic sector, researching substances for addiction treatment. This chart shows the volume of bearish bets. "Shorts" here are bets that the company will fail to pass both the clinical and, even more difficult, legal hurdles to bring such drugs to market.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Clearmind-Medicine-Inc.-CMND&v=1772676512554 "Short Shares Chart for the Company Clearmind Medicine Inc. (CMND)")
Shares shorted by market segment - Pharma psycho
Clearmind Medicine (CMND) is a biotech company developing psychedelic-based drugs (specifically MEAI) for the treatment of addictions, such as alcoholism. This chart aggregates short positions across the biotech sector. It reflects investor skepticism about the psychedelic segment and its regulatory hurdles.
Shares shorted by the overall market
Clearmind Medicine is another biotech company operating in the speculative psychedelic space. This chart illustrates the overall market pessimism. When market fears mount, investors are reluctant to deal with R&D risks coupled with regulatory risks. They are the first to sell off such "hype" stories.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Clearmind Medicine Inc. (CMND)
Clearmind Medicine is another psychedelic company targeting alcoholism treatment. This is a highly speculative market. This chart is a pure indicator of hype. It overheats on any news about R&D progress or decriminalization and cools down due to regulatory barriers.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Clearmind-Medicine-Inc.-CMND&v=1772676512598 "RSI 14 indicator chart for the company's stock Clearmind Medicine Inc. (CMND)")
RSI 14 Market Segment - Pharma psycho
Clearmind (CMND) is a Canadian biotech company operating in the psychedelics sector. They are developing compounds (based on MEAI) for the treatment of addiction. This chart tracks the collective hype in the Psychedelics sector. It shows when the entire industry is overheated by legalization news or oversold by setbacks.
RSI 14 for the overall market
For Clearmind (CMND), a company focused on psychedelics, this chart is an indicator of appetite for hype. During periods of market euphoria, investors are willing to generously fund speculative R&D projects for the "future." During moments of panic, capital flees unprofitable, "conceptual" projects, and companies risk being left without funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CMND (Clearmind Medicine Inc.)
Clearmind Medicine is a biotech company developing psychedelic-based drugs (specifically MEAI) for the treatment of alcohol use disorder (AUD). This chart shows the highly speculative average price target from analysts, based on their confidence in this early R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CMND-Clearmind-Medicine-Inc.&v=1772676512732 "A chart showing analyst consensus forecasts for the expected stock price. CMND (Clearmind Medicine Inc.)")
The difference between the consensus estimate and the actual stock price CMND (Clearmind Medicine Inc.)
Clearmind is a Canadian biotech company developing psychedelic-based drugs (MEAI) for the treatment of alcohol addiction. This chart shows the difference between the market valuation and the consensus forecast. It reveals whether experts believe in this unconventional R&D approach to addiction treatment.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CMND-Clearmind-Medicine-Inc.&v=1772676512747 "A chart showing the difference between the consensus forecast and the actual stock price. CMND (Clearmind Medicine Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma psycho
Clearmind (CMND) is a Canadian psychedelic company developing a DMT derivative (MEAI) for the treatment of alcoholism. This is speculative R&D. This chart shows general expectations for the psychopharma sector. It reflects whether experts believe in the medical potential of psychedelics for treating addiction.
Analysts' consensus forecast for the overall market share price
Clearmind Medicine is a biotech company operating in the psychedelic medicine sector. They are developing drugs (based on MEAI) for the treatment of alcoholism. This chart shows the overall market "risk appetite." For Clearmind, operating in a speculative and not yet fully legalized sector, overall market optimism (risk appetite) is critical for funding.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Clearmind Medicine Inc.
Clearmind is a psychedelic R&D startup. Their signature drug isn't psilocybin, but MEAI (a synthetic molecule), which they're developing as a safe alternative to alcohol (for the treatment of alcoholism). It's a moonshot. This chart is a pure indicator of faith in their R&D. It doesn't reflect revenue, but rather a speculative assessment of their (very risky) pipeline and their chances of success.
AKIMA Market Segment Index - Pharma psycho
Clearmind Medicine (CMND) is a biotech company developing psychedelics 2.0. They focus on creating drugs (based on the MEAI) for the treatment of addictions (alcoholism) and depression that, according to their design, *will* not cause hallucinations. This chart shows the average index for the segment. It helps assess how this safe psycho-strategy compares to the average.
The AKIM Index for the overall market
Clearmind Medicine is a biotech company developing psychedelic drugs (based on the MEAI molecule) for the treatment of alcoholism and binge eating disorder. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this speculative story in new psychiatry compares to overall economic trends.
